# To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours

> **NCT01921140** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 60 (actual)

## Conditions studied

- Solid Tumours

## Interventions

- **DRUG:** Olaparib tablets
- **PROCEDURE:** Pharmacokinetic sampling
- **OTHER:** Dietary Fasted
- **OTHER:** Dietary High Fat

## Key facts

- **NCT ID:** NCT01921140
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-24
- **Primary completion:** 2014-04-08
- **Final completion:** 2022-03-15
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2022-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01921140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01921140, "To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01921140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*